Details for Patent: 8,283,380
✉ Email this page to a colleague
Which drugs does patent 8,283,380 protect, and when does it expire?
Patent 8,283,380 protects XADAGO and is included in one NDA.
This patent has forty-four patent family members in twenty-six countries.
Summary for Patent: 8,283,380
| Title: | Methods for treatment of parkinson's disease |
| Abstract: | New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists. |
| Inventor(s): | Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT) |
| Assignee: | Newron Pharmaceuticals S.p.A. (Bresso, IT) |
| Application Number: | 10/559,982 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,283,380 |
|
Patent Claim Types: see list of patent claims | Use; |
More… ↓ |
Drugs Protected by US Patent 8,283,380
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES | ⤷ Subscribe | |||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,283,380
| PCT Information | |||
| PCT Filed | April 08, 2004 | PCT Application Number: | PCT/IB2004/001408 |
| PCT Publication Date: | October 21, 2004 | PCT Publication Number: | WO2004/089353 |
International Family Members for US Patent 8,283,380
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1613296 | ⤷ Subscribe | CA 2015 00042 | Denmark | ⤷ Subscribe |
| European Patent Office | 1613296 | ⤷ Subscribe | 92782 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 1613296 | ⤷ Subscribe | 300752 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1613296 | ⤷ Subscribe | 241 50017-2015 | Slovakia | ⤷ Subscribe |
| European Patent Office | 1613296 | ⤷ Subscribe | 46/2015 | Austria | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
